Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9TK2

SOS1 IN COMPLEX WITH COMPOUND 3

This is a non-PDB format compatible entry.
Summary for 9TK2
Entry DOI10.2210/pdb9tk2/pdb
DescriptorSon of sevenless homolog 1, ~{N}6-methyl-~{N}2-[(1~{R})-1-phenylethyl]pyridine-2,6-dicarboxamide (3 entities in total)
Functional Keywordsregulatory protein, signaling protein
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight57659.96
Authors
Breed, J. (deposition date: 2025-12-08, release date: 2026-06-24, Last modification date: 2026-07-22)
Primary citationBagal, S.K.,Diene, C.R.N.,Stefanovic-Barrett, S.,Breed, J.,Kauffman, G.W.,Bodnarchuk, M.S.,Collie, G.W.,Staniszewska, A.D.,Srivastava, A.,Irving, E.,Cassar, D.J.,Gray, S.,Hughes, C.,Kettle, J.G.,Nash, S.,Northall, S.,Peter, A.,Schade, M.,Stubbs, C.J.,Smith, A.,Young, L.
Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers.
J.Med.Chem., 69:15277-15293, 2026
Cited by
PubMed Abstract: Son of Sevenless Homologue 1 (SOS1) is a promising oncology target with inhibitors in phase 1/2 clinical studies. A focused HTS triage led to a singular SOS1 series having a pyridyl core. The conformational preference of the diamide pyridyl core was critical to binding potency, leading to pyrazine and pyridyl being the preferred motifs. Application of structure-based design to build into a buried lipophilic pocket led to a significant 50-fold potency enhancement. Strategic fluorination of aryl rings and substituents generated compounds with favorable dipoles, low P-gp and BCRP efflux, and high rat Kp. Multiple analogues were progressed into PK/PD studies where they were combined with a KRAS inhibitor. Combination treated tumors in mice showed deeper, more sustained reductions in DUSP6 mRNA and phosphorylated ERK compared to KRAS inhibitor alone. Thus, these novel CNS penetrant SOS1 inhibitors have potential to enhance antitumor responses when combined with RAS or MAPK inhibitors.
PubMed: 42301273
DOI: 10.1021/acs.jmedchem.5c03800
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.924 Å)
Structure validation

256789

PDB entries from 2026-07-22

PDB statisticsPDBj update infoContact PDBjnumon